Catalog Products » CD58 hFc Chimera, Human
Manual
Manual
COAs

CD58 hFc Chimera, Human

Loss of CD58 is a common mechanism for tumor immune evasion in lymphoid malignancies. CD58 loss is known to occur due to both genetic and non-genetic causes; therefore, we hypothesized that restoring CD58 expression in lymphoma cells may be an effective treatment approach. EZH2 is involved in the epigenetic silencing of CD58 in lymphoma cells as a mechanism for tumor immune escape, and EZH2 inhibitors are able to restore epigenetically suppressed CD58 expression.
$300.00
Z04218-100

Ask us a question
Product Introduction
Species Human
Protein Construction
CD58 (Phe29-Arg215)
Accession # AAH05930		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 48.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD58 HFc Chimera, Human

Affinity of CD2 (his-tagged) captured on his probes with CD58 hFc Chimera, Human »

CD58 HFc Chimera, Human

Immobilized Human CD2, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for CD58 hFc Chimera, Human, hFc Tag with the EC50 of 0.32 μg/ml determined by ELISA. »

CD58 HFc Chimera, Human

The purity of CD58 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

CD58 HFc Chimera, Human

CD58 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Loss of CD58 is a common mechanism for tumor immune evasion in lymphoid malignancies. CD58 loss is known to occur due to both genetic and non-genetic causes; therefore, we hypothesized that restoring CD58 expression in lymphoma cells may be an effective treatment approach. EZH2 is involved in the epigenetic silencing of CD58 in lymphoma cells as a mechanism for tumor immune escape, and EZH2 inhibitors are able to restore epigenetically suppressed CD58 expression.
Synonyms Lymphocyte function-associated antigen 3;Ag3;CD58;LFA3
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.